유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

mylan ireland limited - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunsuppressive - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

teva gmbh - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

노르웨이 - 노르웨이어 - Statens legemiddelverk

sandoz a/s - dimetylfumarat - enterokapsel, hard - 240 mg

노르웨이 - 노르웨이어 - Statens legemiddelverk

sandoz a/s - dimetylfumarat - enterokapsel, hard - 120 mg

유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

노르웨이 - 노르웨이어 - Statens legemiddelverk

glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hard - 240 mg